FDA puts partial hold on Gilead’s CD47 hopeful in AML

The FDA put a partial clinical hold on Gilead’s magrolimab for acute myeloid leukemia, a month after the company scrapped late-stage development of the CD47 candidate in myelodysplastic syndromes.

Gilead said Monday morning it stopped screening and enrolling new patients in US trials studying the drug…
Click here to view original post